QLT Obtains Orphan Drug Status for Drug to Treat Leber Congenital Amaurosis and Retinitis Pigmentosa
December 9, 2010
Submit Comments
Biotech company, QLT Inc., announced earlier this week that the FDA has granted orphan drug designation for QLT091001, its oral synthetic retinoid for the treatment of Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
Click here and here to read the relevant press releases.
Comments
Jump down to form below to submit your own comments
